The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years

✍ Scribed by Rocco G. Piazza; Vera Magistroni; Anna Franceschino; Federica Andreoni; Lucia Tornaghi; Federica Colnaghi; Gianmarco Corneo; Enrico M. Pogliani; Carlo Gambacorti-Passerini

• Book ID: 116304170
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 111 KB
• Volume: 37
• Category: Article
• ISSN: 1079-9796
• DOI: 10.1016/j.bcmd.2006.06.002